Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

PET Imagining in Cardiac Amyloidosis

NYU Langone

S. Dorbala

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Top 5 Arrhythmias You Need to Know

Joel Gorfinkel

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Pulmonary Hypertension: The Basic Essential Facts

Mount Sinai Advanced Heart Disease Symposium 2017

M. Trivieri

Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Hypertrophic Cardiomyopathy: the Past, the Present, and the Future

Canadian Collaborative Research Network

E. Braunwald

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah